Customised app shows promise for monitoring prostate cancer patients in real-time
A pilot study reports high levels of acceptance and compliance despite an older patient population
Why AI-powered trial matching alone will not fix oncology trial recruitment
AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
Counting lines of therapy counts: ESMO leads the way of standardisation
A new ESMO consensus-driven document provides definitions, formats and minimum required data to uniform enumeration and reporting of prior lines of therapy across solid tumours
Phenotypic profiling in pancreatic cancer: promise meets practical limits
COMPASS trial suggests that selecting treatment based on subtypes classification may impact patients’ outcomes, but the approach is hard to implement in clinical practice
Novel emerging targets, new treatment opportunities
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
Rare cancer patients still have limited access to personalised care in Europe
Despite advances in molecular profiling, only a small fraction of patients with actionable alterations receive matched targeted therapies or immunotherapies
Can AI chatbots effectively support patients with cancer during treatments?
Early findings suggest potential benefits in symptom monitoring, but highlight usability challenges and added burden on clinical workflows
Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
CTLA-4 targeting leads to improved overall survival in NSCLC progressing on immunotherapy
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited
Meta-analysis shows non-inferiority of later versus earlier immunotherapy administration in lung cancer
Chrono-immunotherapy may influence treatment outcomes, especially during the early phase of treatment, but its overall clinical impact remains to be clearly defined